We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.
- Authors
Angelopoulou, Maria K.; Vassilakopoulos, Theodoros P.; Batsis, Ioannis; Sakellari, Ioanna; Gkirkas, Konstantinos; Pappa, Vasiliki; Giannoulia, Panagiota; Apostolidis, Ioannis; Apostolopoulos, Christos; Roussou, Paraskevi; Panayiotidis, Panayiotis; Dimou, Maria; Kyrtsonis, Marie‐Christine; Palassopoulou, Maria; Vassilopoulos, Georgios; Moschogiannis, Maria; Kalpadakis, Christina; Margaritis, Dimitrios; Spyridonidis, Alexander; Michalis, Eurydiki
- Abstract
This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety-five patients with R/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% were males. Sixty-seven patients received BV after autologous stem cell transplantation failure, whereas 28 patients were treated with BV without a prior autologous stem cell transplantation, due to advanced age/comorbidities or chemorefractory disease. The median number of prior treatments was 4 and 44% of the patients were refractory to their most recent therapy. The median number of BV cycles was 8 (range, 2-16), and the median time to best response was the fourth cycle. Fifty-seven patients achieved an objective response: twenty-two (23%), a complete response (CR), and 35 patients (37%), a partial, for an overall response rate of 60%. Twelve patients (13%) had stable disease, and the remaining twenty-six (27%) had progressive disease as their best response. At a median follow-up of 11.5 months, median progression-free survival and overall survival were 8 and 26.5 months, respectively. Multivariate analysis showed that chemosensitivity to treatment administered before BV was associated with a significantly increased probability of achieving response to BV (P = .005). Bulky disease (P = .01) and response to BV (P <.001) were significant for progression-free survival, while refractoriness to most recent treatment (P = .04), bulky disease (P = .005), and B-symptoms (P = .001) were unfavorable factors for overall survival. Among the 22 CRs, 5 remain in CR with no further treatment after BV at a median follow-up of 13 months. In conclusion, our data indicate that BV is an effective treatment for R/R HL patients even outside clinical trials. Whether BV can cure a fraction of patients remains to be seen.
- Subjects
THERAPEUTIC use of immunoglobulins; COMPARATIVE studies; HODGKIN'S disease; IMMUNOGLOBULINS; RESEARCH methodology; MEDICAL cooperation; PROGNOSIS; RESEARCH; SURVIVAL analysis (Biometry); EVALUATION research; TREATMENT effectiveness; RETROSPECTIVE studies
- Publication
Hematological Oncology, 2018, Vol 36, Issue 1, p174
- ISSN
0278-0232
- Publication type
journal article
- DOI
10.1002/hon.2383